Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet 2023 Nov 23
The effectiveness of antibacterial therapeutic clothing compared with non-antibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: A randomized controlled, observer-blind pragmatic trial (ABC trial). Br J Dermatol 2023 Nov 04
Prevalence and healthcare usage of Chronic Urticaria in Primary Care: A Population-Based Study in The Netherlands. Br J Dermatol 2023 Oct 28
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. N Engl J Med 2023 Oct 26; 389(17):1579-1589
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis. JAMA Dermatol 2023 Nov 01; 159(11):1240-1247
Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe. J Eur Acad Dermatol Venereol 2023 Sep 13
A concept for integrated care pathways for atopic dermatitis-A GA LEN ADCARE initiative. Clin Transl Allergy 2023 Sep; 13(9):e12299
IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval. Clin Exp Allergy 2023 Nov; 53(11):1222-1225
Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps. J Dermatolog Treat 2023 Dec; 34(1):2254567
Prognostic Factors for Long-term Aesthetic Outcome of Infantile Haemangioma Treated with Beta-blockers. Acta Derm Venereol 2023 Aug 30; 103:adv5286
Age and fast initial response predict omalizumab retreatment in chronic urticaria. J Allergy Clin Immunol Pract 2023 Nov; 11(11):3556-3558.e1
Correction to: Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. Eur J Pediatr 2023 Sep; 182(9):4285-4287
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol 2023 Oct; 37(10):2056-2066
A European-Japanese study on peach allergy: IgE to Pru p 7 associates with severity. Allergy 2023 Sep; 78(9):2497-2509
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16. Adv Ther 2023 Aug; 40(8):3574-3587